Last reviewed · How we verify
NCT05142982
Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced Seminoma
NA trial testing Radiotherapy in Seminoma in 74 participants. Currently enrolling.
15 December 2029
Quick facts
| Lead sponsor | Tata Memorial Centre |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 74 |
| Start date | 1 December 2021 |
| Primary completion | 15 December 2029 |
| Estimated completion | 15 December 2029 |
| Sites | 2 locations across India |
Drugs / interventions tested
- Radiotherapy — full drug profile →
Conditions studied
- Seminoma — all drugs for Seminoma →
Sponsor
Tata Memorial Centre — full company profile →
Who can join
Adults 18 to 80, male only, with Seminoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Testicular tumors account for 1% of all cancers in males and germ cell tumors comprise 95% of all testicular cancers. Seminomas consist of around 50% of cases. However,adequate information is not there as 60- 80% residual disease is seen even after with the standard management of chemotherapy. With the advent of functional imaging there was hope that it could aid in more accurately targeting these tumors to systematically evaluate the role of PET-CT imaging in identifying patients diagnosed with stage IIB-IIIC seminomatous germ cell tumor, with residual visible tumor post chemotherapy who would benefit with loco regional radiotherapy. The therapeutic research in Seminomashas been relatively slow and such structured studies can allow analysis of large number of patients to report on acute and late effect of treatment outcomes using CTCAE and QOL (EORTC QLQ C-30) in these cancers. We hope that we will get help in identifying thrust areas for future research through this study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05142982
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Radiotherapy
Trials testing the same drug.
- NCT07497607 — Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma · Phase 2 · not yet recruiting
- NCT06813664 — ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI) · Phase 2 · not yet recruiting
- NCT07339774 — Traditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients · Phase 2 · recruiting
- NCT07353671 — Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis · Phase 2, PHASE3 · recruiting
- NCT07245745 — Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer · NA · recruiting
Other recruiting trials for Seminoma
Currently open trials in the same condition.
- NCT07498959 — Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer · NA · recruiting
- NCT06309745 — THERApy De-escalation for TESTicular Cancer · recruiting
- NCT06133543 — Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer · NA · recruiting
- NCT06144736 — PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND · Phase 2 · recruiting
- NCT05529251 — De-escalation Study for Stage IIa/IIb < 3 cm Seminoma · Phase 2 · recruiting
Other Tata Memorial Centre trials
Trials by the same sponsor.
- NCT07236840 — Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors · recruiting
- NCT06492486 — Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow · Phase 2 · not yet recruiting
- NCT07338539 — BIO-SHORT: Biologically Guided Short-Course Hypofractionated RT for Poor-Prognosis GBM · Phase 2 · recruiting
- NCT07395635 — Phase II Trial of Immunonutrition in Hepatectomy · NA · recruiting
- NCT07338526 — Intensity Modulated PrOton Therapy in Pediatric BRain Tumors (IMPORT) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05142982 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tata Memorial Centre
- Last refreshed: 11 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05142982.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing